The validity of the early use of combined mucoactive drugs in respiratory infections in children
Year: 2024
Type: article
Abstract: According to the Weekly National Bulletin on Influenza and SARS and other epidemiological studies, the incidence of SARS and influenza still holds a leading position among all infectious diseases. And, in addition to fever, the most common complaint and reason for seeking medical help in outpatient practice is cough, both as a symptom of acute respiratory infection (ARI) and as a symptom of complications. Among the complications of ARI, bronchopulmonary diseases such as acute bronchitis, chronic bronchitis, bronchiectasis, etc. are most common. Cough appears from the first days of the disease, pronounced, unproductive at the beginning of the disease, sometimes it can be accompanied by parasternal pain as a result of strong coughing shocks. Bronchial obstruction syndrome may be observed. That is why effective pathophysiological treatment of patients with ARI is the most important task of modern pharmacotherapy. According to research data, combined drugs have the most pronounced mucoactive effect in cough syndrome with ARI. The article considers the mechanism of action of the combined oral drug, which contains such active ingredients as bromhexine hydrochloride, salbutamol sulfate, guaifenesin, the time of onset of action of these substances, transformations, as well as the need for cough therapy in the earliest possible time from the onset of the disease.
DOI: 10.21518/ms2024-334
Authors: L. S. Starostina, L. I. Karzhavina
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4402221581